Abstract
OBJECTIVE: Quantitative comparison of the diagnostic value of spectral CT imaging and conventional CT post-processing technique in differentiating malignant and benign renal tumors. METHODS: A total of 209 patients with renal tumors who had undergone CT enhancement were assigned to three groups-clear cell renal cell carcinoma (ccRCC, n = 106), non-ccRCC (n = 60), and benign renal tumor (n = 43) groups. Parametric CT enhancement of each tumor based on spectral CT and conventional CT was performed using in-house software, and the iodine concentration, water content, slope, and density values among the three groups were compared. The receiver operating characteristic (ROC) curve analysis was performed to determine the optimum diagnostic thresholds, the area under the ROC curve (AUC), sensitivity, specificity, and accuracy of the above parameters. RESULTS: The iodine concentration, slope, and density values were higher in the ccRCCs group compared to the non-ccRCCs and benign renal tumor groups (p < 0.05). Moreover, the iodine concentration, slope, and density values were higher in benign renal tumors compared to non-ccRCCs (p < 0.05). According to the ROC curve analysis, iodine concentration presented the highest diagnostic efficacy in differentiating ccRCCs/non-ccRCCs from benign renal tumors. The pairwise comparisons of the ROC curves and the diagnostic efficacies revealed that ROI-based CT enhancement was worse than the spectral CT imaging analysis in terms of density (p < 0.05). CONCLUSION: Iodine concentration presented the highest diagnostic efficacy in differentiating ccRCCs/non-ccRCCs from benign renal tumors. ADVANCES IN KNOWLEDGE: 1. The iodine concentration, slope, and density values were higher for the ccRCCs compared to non-ccRCCs and benign renal tumors.2. Iodine concentration presented the highest diagnostic efficacy in differentiating ccRCCs/non-ccRCCs from benign renal tumors.3. Spectral CT imaging analysis performed better than conventional CT in differentiating malignant and benign renal tumors.